Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LTK | P29376 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | MST1R | Q04912 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033117 | 0.68 | ALDH1A1 (0.34) | ADORA3ALDH1A1LTKALKDYRK1B | |
| SCHEMBL19152456 | 0.68 | CCNE1 (0.42) | ADORA3CCNE1CDK2CLK4PARP1 | |
| SCHEMBL557383 | 0.68 | MAP2K1 (0.44) | ADORA3CCNE1CDK2DYRK1BCDK8 | |
| SCHEMBL10250849 | 0.65 | CCNE1 (0.41) | XDHCCNE1CDK2LTKALK | |
| SCHEMBL12102068 | 0.65 | PARP1 (0.41) | ADORA3ALDH1A1KDM4ESMN1; SMN2PARP1 | |
| SCHEMBL2643830 | 0.65 | XDH (0.41) | XDHCCNE1CDK2ALDH1A1CCNE2 | |
| SCHEMBL3749203 | 0.65 | NPC1 (0.48) | ALDH1A1METKDM4ESMN1; SMN2PARP1 | |
| SCHEMBL11075249 | 0.64 | LTK (0.49) | ADORA3ALDH1A1LTKALKDYRK1B | |
| SCHEMBL2769675 | 0.64 | ADORA3 (0.53) | ADORA3ALDH1A1KDM4ESMN1; SMN2PARP1 | |
| SCHEMBL867071 | 0.64 | KDR (0.35) | XDHALDH1A1ABL1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2022-02-03 | — | — | US | disclosed |
| US-10981915-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190308980-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10351571-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180339991-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
| CN-103649089-B | Pyrrolotriazinones as PI3K inhibitors | 阿尔米雷尔有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| EP-2336123-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | Neopharm Co., Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2288611-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| US-7851500-B2 | Aminopyrazole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100022503-A1 | AMINOPYRAZOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| EP-2111402-A2 | AMINOPYRAZOLE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009117157-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008086128-A2 | AMINOPYRAZOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20060135767-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-06-22 | — | — | US | disclosed |
| JP-2000330245-A | SILVER HALIDE COLOR PHOTOSENSITIVE MATERIAL | FUJI PHOTO FILM CO LTD | 2000-11-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135767-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | ADORA3 870/4885XDH 236/4885CCNE1 1450/4885 |
| US-20100022503-A1 | AMINOPYRAZOLE KINASE INHIBITORS | ABL1, MAP3K19, MAP3K20 | ADORA3 1704/4885XDH 893/4885CCNE1 684/4885 |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
| US-10981915-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
| US-20190308980-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | ADORA3 1193/4885XDH 4363/4885CCNE1 9/4885 |
| US-20180339991-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
| US-10351571-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ADORA3 4462/4885XDH 404/4885CCNE1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.